文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在澳大利亚和新西兰开致幻剂治疗处方的情况：对精神科医生的简要调查。

The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists.

机构信息

4334The University of Sydney, NSW, Australia.

School of Medicine and Psychology, 2219Australian National University, Canberra, ACT, Australia.

出版信息

Australas Psychiatry. 2023 Apr;31(2):190-194. doi: 10.1177/10398562231156684. Epub 2023 Feb 13.

DOI:10.1177/10398562231156684
PMID:36779819
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10088334/
Abstract

OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions. RESULTS: Fifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future. CONCLUSION: Considering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists.

摘要

目的：探讨精神科医生对迷幻药治疗的知识和态度。

方法：通过社交媒体渠道向精神科医生发放横断面调查。使用李克特量表和排序问题记录对迷幻药治疗的态度和知识。

结果：共收集到 58 份完整回复（44 名完全受训+14 名 RANZCP 受训成员）。超过 85%的受访者同意有效的精神科治疗方法存在不足，超过 65%的受访者同意迷幻药治疗可能会解决这一不足。精神科医生认为自己对迷幻药治疗方法并不了解，有 60%的人对这一主题的进一步培训表示感兴趣。大约 70%的样本对迷幻药治疗方法持有各种顾虑，更多的人认为迷幻药物的处方未来应仅限于精神科医生。

结论：考虑到与迷幻药研究和法规迅速变化的相关背景，我们认为有必要为精神科医生提供有关迷幻药的最新教育。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d903/10088334/de68a4230a72/10.1177_10398562231156684-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d903/10088334/d640f40a9d17/10.1177_10398562231156684-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d903/10088334/de68a4230a72/10.1177_10398562231156684-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d903/10088334/d640f40a9d17/10.1177_10398562231156684-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d903/10088334/de68a4230a72/10.1177_10398562231156684-fig2.jpg

相似文献

[1]
The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists.

Australas Psychiatry. 2023-4

[2]
Re The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists.

Australas Psychiatry. 2023-10

[3]
A survey of Australian psychiatrists' and psychiatry trainees' knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders.

Australas Psychiatry. 2023-6

[4]
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.

Psychiatr Serv. 2023-8-1

[5]
Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study.

Sci Rep. 2024-8-12

[6]
Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.

Aust N Z J Psychiatry. 2024-10

[7]
Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey.

J Psychoactive Drugs. 2022

[8]
[Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland].

Laeknabladid. 2023-11

[9]
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.

J Acad Consult Liaison Psychiatry. 2021

[10]
Psychedelic-assisted therapies: The past, and the need to move forward responsibly.

Int J Drug Policy. 2019-5-25

引用本文的文献

[1]
Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers.

Aust N Z J Psychiatry. 2025-7-15

[2]
Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.

Aust N Z J Psychiatry. 2024-10

[3]
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.

Aust N Z J Psychiatry. 2024-7

[4]
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential.

Mol Psychiatry. 2024-3

本文引用的文献

[1]
Evaluating the attitudes of mental health professionals towards trials of MDMA: a randomised vignette trial.

BMJ Open. 2022-11-25

[2]
Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.

Int J Drug Policy. 2022-10

[3]
Psychedelic drugs-a new era in
psychiatry?
.

Dialogues Clin Neurosci. 2019

[4]
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.

Front Psychiatry. 2019-9-12

[5]
The Australian drug harms ranking study.

J Psychopharmacol. 2019-5-13

[6]
Unifying Theories of Psychedelic Drug Effects.

Front Pharmacol. 2018-3-2

[7]
Psychiatry & the psychedelic drugs. Past, present & future.

Neuropharmacology. 2017-12-25

[8]
Drug harms in the UK: a multicriteria decision analysis.

Lancet. 2010-10-29

[9]
A review of the clinical effects of psychotomimetic agents.

Ann N Y Acad Sci. 1957-3-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索